Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
Established supply capacity to enable broad, equitable access towards 3bn doses worldwide
R-Pharm
Doses TBC
SK Bioscience
20mEU Commission
Up to 400m
UK
100m
Fiocruz
100m
Carlos Slim
(Liomont/Mabxience)
150m
CSL
53.8m
Japan
120m
Canada
20m
US
300m
Israel
10m
SBS, SCG
Doses TBC
SII
1 bn
1
Establishing parallel supply
agreements to ensure global
access:
Brazil (Fiocruz)
LatAm (Ex Brazil)
Japan
China
South Korea
Russia with export
to MEA, CIS, Balkans
(R-Pharm)
July
USAMay
UKApril
EuropeAugust
AustraliaSeptember
SII (LMIC)June
CanadaNovember
Israel
CEPI-GAVI COVAX
SE AsiaOctober
Continued engagement with intl. orgs and govts to drive equitable access
CEPI-Gavi / COVAX – 170m
= Countries that have committed to the COVAX Facility as
of December 15
BioKangtai
Up to 200m
New Zealand
7.5m
New ZealandDecember